Full history for every metric is available with a Kvantra account
Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ)
Key financial summary
Financials in CNY| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY bn | 31 | 50 | 44 | 50 | 50 | 50 | 82 |
| Operating profit | CNY bn | 1 | 1 | |||||
| Net profit | CNY bn | 1 | 3 | 1 | 1 | 1 | -1 | -1 |
| EPS reported | CNY | -0.13 | -0.11 | |||||
| Operating cashflow per share | CNY | 1.90 | 1.90 | |||||
| Capex per share | CNY | 0.01 | 0.01 | |||||
| FCF per share | CNY | 1.89 | 1.89 | |||||
| Free cash flow | CNY bn | 9 | -19 | |||||
| Net debt | CNY bn | -5 | 7 | |||||
| Book value equity | CNY bn | 21 | 22 | |||||
| Book value per share | CNY | 4.11 | 4.41 | |||||
| Number of shares | m | 5,013.53 | 4,940.63 | |||||
| DPS (TTM paid) | CNY | 0.11 | 0.00 |
Financial summary
Financials in CNY| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.68 | 0.36 | |||||
| P/S LTM | x | 0.28 | 0.09 | |||||
| P/FCF LTM | x | 1.49 | -0.40 | |||||
| EV/EBITDA LTM | x | -11.36 | 2.85 | |||||
| EV/Sales LTM | x | 0.23 | 0.18 | |||||
| Earnings Yield LTM | % | -4.63% | -8.23% | |||||
| FCF Yield | % | 67.20% | -248.13% | |||||
| Quality | ||||||||
| ROE | % | -3.17% | -3.10% | |||||
| ROIC | % | 0.28% | 0.28% | |||||
| Operating margin | % | 2.45% | 2.45% | |||||
| Gross margin | % | 80.22% | 80.22% | |||||
| FCF/Sales | % | 19.05% | 19.05% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +0.17% | +54.73% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | +28.12% | - | |||||
| Operating Profit Growth | % | -96.10% | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 3.86% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -83.39% | -176.88% | |||||
| FCF/Debt | x | 0.37 | -1.10 | |||||
| Net Debt/EBITDA | x | 2.74 | 2.74 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -32.69% | 89.26% | |||||
| Net debt/Equity | x | -0.22 | 0.32 | |||||
| Gross debt/equity | x | 1.23 | 0.81 | |||||
Company overview
Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a multifaceted business. Its primary activities within China involve the provision of life and motor insurance policies. Additionally, the company is engaged in the pharmaceutical, chemical, and new energy fuel industries. Specifically, in the pharmaceutical field, it conducts contract research, development, and manufacturing of active pharmaceutical ingredients (APIs), intermediate compounds, and various drug forms such as tablets, granules, and capsules. Its chemical offerings include substances like dimethyl ether gas and a-chloropropionyl chloride. The firm also boasts an international presence, distributing its products to markets including the United States, the European Union, and other global locations.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ)
Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a multifaceted business. Its primary activities within China involve the provision of life and motor insurance policies. Additionally, the company is engaged in the pharmaceutical, chemical, and new energy fuel industries. Specifically, in the pharmaceutical field, it conducts contract research, development, and manufacturing of active pharmaceutical ingredients (APIs), intermediate compounds, and various drug forms such as tablets, granules, and capsules. Its chemical offerings include substances like dimethyl ether gas and a-chloropropionyl chloride. The firm also boasts an international presence, distributing its products to markets including the United States, the European Union, and other global locations.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free